Concepts (178)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adenocarcinoma | 9 | 2024 | 999 | 1.860 |
Why?
|
| Pancreatic Neoplasms | 6 | 2024 | 688 | 1.410 |
Why?
|
| Colorectal Neoplasms | 5 | 2025 | 562 | 0.940 |
Why?
|
| Circulating Tumor DNA | 2 | 2022 | 32 | 0.890 |
Why?
|
| Oncolytic Viruses | 1 | 2024 | 71 | 0.870 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 230 | 0.790 |
Why?
|
| Ikaros Transcription Factor | 2 | 2022 | 28 | 0.770 |
Why?
|
| Transaminases | 2 | 2022 | 33 | 0.760 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2023 | 154 | 0.750 |
Why?
|
| Anemia | 1 | 2024 | 340 | 0.690 |
Why?
|
| Safety-net Providers | 1 | 2020 | 43 | 0.660 |
Why?
|
| Colonic Neoplasms | 2 | 2019 | 254 | 0.650 |
Why?
|
| Oncologists | 1 | 2019 | 29 | 0.630 |
Why?
|
| Documentation | 1 | 2019 | 115 | 0.610 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2018 | 76 | 0.600 |
Why?
|
| Exophthalmos | 1 | 2018 | 37 | 0.590 |
Why?
|
| Healthcare Disparities | 2 | 2020 | 419 | 0.590 |
Why?
|
| Minority Groups | 1 | 2020 | 251 | 0.590 |
Why?
|
| Needs Assessment | 1 | 2019 | 173 | 0.590 |
Why?
|
| Bacteremia | 2 | 2021 | 405 | 0.580 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 101 | 0.570 |
Why?
|
| Orbital Neoplasms | 1 | 2018 | 65 | 0.570 |
Why?
|
| Neuroendocrine Tumors | 1 | 2018 | 52 | 0.570 |
Why?
|
| Cholangiocarcinoma | 1 | 2018 | 110 | 0.570 |
Why?
|
| Neoadjuvant Therapy | 6 | 2023 | 321 | 0.570 |
Why?
|
| Orbit | 1 | 2018 | 103 | 0.560 |
Why?
|
| Rectal Neoplasms | 3 | 2023 | 76 | 0.530 |
Why?
|
| Oncolytic Virotherapy | 1 | 2017 | 83 | 0.520 |
Why?
|
| Stomach Neoplasms | 3 | 2019 | 538 | 0.520 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2014 | 4 | 0.480 |
Why?
|
| Cholestasis, Extrahepatic | 1 | 2014 | 8 | 0.480 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2014 | 20 | 0.470 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 501 | 0.470 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 1250 | 0.440 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 710 | 0.420 |
Why?
|
| Physicians | 1 | 2019 | 583 | 0.410 |
Why?
|
| Electronic Health Records | 1 | 2019 | 697 | 0.410 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 3 | 2018 | 61 | 0.380 |
Why?
|
| Neoplasm Staging | 7 | 2023 | 1222 | 0.340 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 1389 | 0.300 |
Why?
|
| Aged | 11 | 2022 | 18998 | 0.300 |
Why?
|
| Aspergillosis | 2 | 2004 | 42 | 0.300 |
Why?
|
| Middle Aged | 13 | 2025 | 25885 | 0.290 |
Why?
|
| Tumor Microenvironment | 2 | 2024 | 538 | 0.280 |
Why?
|
| Lymphatic Metastasis | 2 | 2019 | 399 | 0.280 |
Why?
|
| Neoplasms | 1 | 2021 | 2751 | 0.270 |
Why?
|
| Adult | 15 | 2025 | 28944 | 0.270 |
Why?
|
| Humans | 29 | 2025 | 122971 | 0.270 |
Why?
|
| Paclitaxel | 2 | 2024 | 122 | 0.270 |
Why?
|
| Anal Canal | 2 | 2023 | 81 | 0.260 |
Why?
|
| Mannans | 1 | 2004 | 10 | 0.240 |
Why?
|
| Aspergillus | 1 | 2004 | 31 | 0.240 |
Why?
|
| Lung Diseases, Fungal | 1 | 2004 | 33 | 0.240 |
Why?
|
| Female | 15 | 2025 | 65361 | 0.240 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2004 | 158 | 0.230 |
Why?
|
| Male | 15 | 2025 | 59957 | 0.230 |
Why?
|
| Albumins | 1 | 2024 | 90 | 0.220 |
Why?
|
| Bayes Theorem | 1 | 2024 | 265 | 0.210 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2020 | 1006 | 0.200 |
Why?
|
| Communicable Diseases | 1 | 2004 | 163 | 0.200 |
Why?
|
| Cost-Benefit Analysis | 2 | 2015 | 498 | 0.200 |
Why?
|
| Blood Culture | 1 | 2021 | 29 | 0.190 |
Why?
|
| DNA Methylation | 2 | 2025 | 993 | 0.180 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 1598 | 0.180 |
Why?
|
| Gastrointestinal Diseases | 1 | 2004 | 337 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 1119 | 0.180 |
Why?
|
| Epigenesis, Genetic | 1 | 2025 | 667 | 0.170 |
Why?
|
| Lymph Nodes | 2 | 2019 | 377 | 0.170 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 169 | 0.170 |
Why?
|
| Cancer Vaccines | 1 | 2022 | 187 | 0.170 |
Why?
|
| Fraud | 1 | 2019 | 16 | 0.170 |
Why?
|
| Genetic Therapy | 1 | 2024 | 706 | 0.170 |
Why?
|
| Acute Disease | 2 | 2018 | 1092 | 0.170 |
Why?
|
| Medically Uninsured | 1 | 2020 | 73 | 0.160 |
Why?
|
| Carcinoma, Small Cell | 1 | 2019 | 50 | 0.160 |
Why?
|
| Leucovorin | 3 | 2023 | 50 | 0.160 |
Why?
|
| DNA Mismatch Repair | 1 | 2018 | 48 | 0.160 |
Why?
|
| Mass Screening | 2 | 2015 | 786 | 0.160 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 6343 | 0.160 |
Why?
|
| Fluorouracil | 3 | 2023 | 139 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 2048 | 0.150 |
Why?
|
| Physical Examination | 1 | 2019 | 163 | 0.150 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 298 | 0.150 |
Why?
|
| Gastrectomy | 1 | 2019 | 89 | 0.150 |
Why?
|
| Genetic Testing | 2 | 2015 | 995 | 0.150 |
Why?
|
| Algorithms | 2 | 2015 | 1583 | 0.150 |
Why?
|
| Myxoma virus | 1 | 2017 | 1 | 0.140 |
Why?
|
| Parvovirus | 1 | 2017 | 8 | 0.140 |
Why?
|
| Orthoreovirus, Mammalian | 1 | 2017 | 7 | 0.140 |
Why?
|
| Measles virus | 1 | 2017 | 10 | 0.140 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2018 | 88 | 0.140 |
Why?
|
| Vaccinia virus | 1 | 2017 | 52 | 0.140 |
Why?
|
| Simplexvirus | 1 | 2017 | 110 | 0.140 |
Why?
|
| Immunotherapy | 1 | 2022 | 656 | 0.140 |
Why?
|
| Retrospective Studies | 5 | 2021 | 15934 | 0.140 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 866 | 0.130 |
Why?
|
| Ethics, Medical | 1 | 2019 | 395 | 0.130 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 416 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 1034 | 0.120 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2023 | 366 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2014 | 53 | 0.120 |
Why?
|
| Histocytochemistry | 1 | 2014 | 106 | 0.120 |
Why?
|
| Adenoviridae | 1 | 2017 | 636 | 0.110 |
Why?
|
| Radiography, Thoracic | 1 | 2014 | 156 | 0.110 |
Why?
|
| Microscopy | 1 | 2014 | 119 | 0.110 |
Why?
|
| Esophagoscopy | 1 | 2014 | 158 | 0.110 |
Why?
|
| Organ Sparing Treatments | 2 | 2023 | 34 | 0.110 |
Why?
|
| Health Status Disparities | 1 | 2015 | 219 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 1086 | 0.100 |
Why?
|
| Deoxycytidine | 2 | 2023 | 77 | 0.100 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 1717 | 0.090 |
Why?
|
| Chemoradiotherapy | 2 | 2023 | 101 | 0.090 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 1247 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 2396 | 0.080 |
Why?
|
| Preoperative Care | 2 | 2023 | 351 | 0.080 |
Why?
|
| Disease-Free Survival | 2 | 2023 | 868 | 0.080 |
Why?
|
| Treatment Outcome | 5 | 2023 | 12083 | 0.070 |
Why?
|
| Foodborne Diseases | 1 | 2004 | 11 | 0.060 |
Why?
|
| Meningococcal Vaccines | 1 | 2005 | 30 | 0.060 |
Why?
|
| Protozoan Infections | 1 | 2004 | 12 | 0.060 |
Why?
|
| Splenectomy | 1 | 2005 | 61 | 0.060 |
Why?
|
| Galactose | 1 | 2004 | 55 | 0.060 |
Why?
|
| United States | 4 | 2025 | 10564 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 1 | 2004 | 268 | 0.060 |
Why?
|
| Young Adult | 4 | 2019 | 8830 | 0.060 |
Why?
|
| Itraconazole | 1 | 2003 | 25 | 0.060 |
Why?
|
| Fluconazole | 1 | 2003 | 47 | 0.050 |
Why?
|
| Pneumococcal Vaccines | 1 | 2005 | 168 | 0.050 |
Why?
|
| Age of Onset | 1 | 2025 | 581 | 0.050 |
Why?
|
| Preoperative Period | 1 | 2023 | 82 | 0.050 |
Why?
|
| Survival Rate | 2 | 2019 | 1999 | 0.050 |
Why?
|
| Antibodies, Bacterial | 1 | 2005 | 382 | 0.050 |
Why?
|
| Pneumococcal Infections | 1 | 2005 | 274 | 0.050 |
Why?
|
| Streptococcus pneumoniae | 1 | 2005 | 372 | 0.050 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2022 | 21 | 0.050 |
Why?
|
| Virus Diseases | 1 | 2004 | 280 | 0.050 |
Why?
|
| Bacterial Infections | 1 | 2004 | 305 | 0.050 |
Why?
|
| Stem Cell Transplantation | 1 | 2003 | 239 | 0.050 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2023 | 164 | 0.050 |
Why?
|
| Registries | 2 | 2019 | 1381 | 0.050 |
Why?
|
| Incidence | 3 | 2017 | 3040 | 0.050 |
Why?
|
| Antifungal Agents | 1 | 2003 | 293 | 0.050 |
Why?
|
| Standard of Care | 1 | 2022 | 128 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 232 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 2025 | 0.040 |
Why?
|
| Prognosis | 2 | 2019 | 4503 | 0.040 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 68 | 0.040 |
Why?
|
| False Negative Reactions | 1 | 2019 | 89 | 0.040 |
Why?
|
| Drug Therapy | 1 | 2019 | 87 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2019 | 144 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2019 | 140 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2022 | 1473 | 0.040 |
Why?
|
| Recurrence | 1 | 2022 | 1419 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 267 | 0.040 |
Why?
|
| Rectum | 1 | 2018 | 97 | 0.040 |
Why?
|
| General Surgery | 1 | 2019 | 203 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2019 | 422 | 0.030 |
Why?
|
| Stomach | 1 | 2019 | 273 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2004 | 1193 | 0.030 |
Why?
|
| Animals | 1 | 2017 | 33923 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2019 | 1240 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2025 | 4688 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 1301 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2022 | 1431 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 1164 | 0.030 |
Why?
|
| Biomarkers | 1 | 2023 | 2952 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 1491 | 0.030 |
Why?
|
| Quality of Life | 1 | 2023 | 1921 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 2104 | 0.030 |
Why?
|
| Adolescent | 2 | 2019 | 19043 | 0.020 |
Why?
|
| Texas | 1 | 2017 | 3542 | 0.020 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2005 | 25 | 0.020 |
Why?
|
| Drug Resistance, Fungal | 1 | 2003 | 25 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 3084 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2005 | 771 | 0.010 |
Why?
|
| Risk Factors | 1 | 2015 | 9950 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 2003 | 543 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2005 | 3002 | 0.010 |
Why?
|